Novel therapies for osteoporosis.

摘要: Since the identification of osteoporosis as a major health issue in aging populations and subsequent development first treatment modalities for its management, considerable progress has been made our understanding mechanisms controlling bone turnover disease pathophysiology, thus enabling pinpointing new targets intervention. This progress, along with advances biotechnology, rendered possible ever more sophisticated treatments employing novel action. Denosumab, monoclonal antibody against RANKL, approved postmenopausal male osteoporosis, significantly continuously increases mineral density (BMD) maintains low risk vertebral, non-vertebral, hip fractures up to 8 years. Currently available combinations estrogens selective estrogen receptor modulators moderately increase BMD without causing extra-skeletal adverse effects each compound alone. The cathepsin K inhibitor odanacatib recently shown decrease fracture rates is nearing approval. Romosozumab, an anti-sclerosin antibody, abaloparatide, PTH-related peptide analog, are at present advanced stages clinical evaluation, so far demonstrating efficaciousness together favorable safety profile. Several other agents currently earlier preclinical phases development, including dickkopf-1 antagonists, activin A β-arrestin analogs, calcilytics, Src tyrosine kinase inhibitors.